scholarly journals Apelin Serum Level in Egyptian Patients with Chronic Hepatitis C

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Hala O. El-Mesallamy ◽  
Nadia M. Hamdy ◽  
Hanan H. Rizk ◽  
Abdel-Rahman El-Zayadi
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Orphan Receptor ◽  
Necrosis Factor Alpha ◽  
Factors Affecting ◽  
Fibrosis Progression ◽  
Egyptian Patients ◽  
Factor Alpha ◽  
Nonobese Patients

Objective. Highlighting the apelin system would present a new therapeutic target for liver disease. Apelin; endogenous ligand for the orphan receptor APJ, was recently suggested to be associated with fibrosis progression and cirrhosis in addition to insulin resistance (IR) and inflammation. The present study was conducted to evaluate blood apelin level changes among 73 chronic hepatitis C (CHC) Egyptian patients and if associated with body mass index (BMI), IR, and tumor necrosis factor-alpha (TNF-α). Serum apelin levels were significantly higher in patients with CHC with median value (3.25) when compared with controls (1.11), atP<0.0001, with significant apelin variations among asymptomatic carriers (ASC), fibrosis, and cirrhosis patients, and also among obese and nonobese patients. Multiple regression analysis depicted that BMI, triglycerides, and total cholesterol were independent correlation factors to apelin levels, whereas TNF-αwas found to be significantly negatively correlated to adjusted apelin in CHC patients (r=−0.5944,P<0.0001). IR was positively correlated to adjusted apelin in CHC patients (r=0.2663,P<0.05).Conclusion. Apelin level varies among stages of CHC, which may contribute to fibrosis progression. In addition, obesity and IR could act as comorbid factors affecting apelin level in patients with CHC.

Tumour necrosis factor alpha polymorphisms are not involved in the development of steatosis in chronic hepatitis C

2004 ◽  
Vol 16 (8) ◽  
pp. 761-765 ◽  
Author(s):  
Diego S??nchez-Mu??oz ◽  
Manuel Romero-G??mez ◽  
Maria F Gonz??lez-Escribano ◽  
Belen Torres ◽  
Victor M Castellano-Megias ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Tumour Necrosis Factor ◽  
Chronic Hepatitis C ◽  
Tumour Necrosis ◽  
Tumour Necrosis Factor Alpha ◽  
Necrosis Factor Alpha ◽  
Factor Alpha ◽  
Necrosis Factor

Asymptomatic chronic hepatitis C with F0-1 fibrosis: Treat now

2018 ◽  
Vol 1 (2) ◽  
pp. 9-13
Author(s):  
Supatsri Sethasine
Keyword(s):  
Chronic Hepatitis ◽  
Cost Effectiveness ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Entire Group ◽  
Advanced Fibrosis ◽  
Factors Affecting ◽  
Fibrosis Progression ◽  
Life Years ◽  
Treatment Naïve

Patients with chronic hepatitis C with no or minimal liver fibrosis (F0-F1 Fibrosis) were 50% of the entire group of patients with chronic hepatitis C. Although this group of patients might have to defer treatment due to treatment prioritization strategy, as the excellent performance of regimens with few side-effects, if in the future they would have access the treatment, the number of patient with chronic hepatitis C would decrease dramatically. After following up with treatment-naive patients for five years, 60% of them had the fibrosis progression. Patients with minimal fibrosis had possibility of advanced fibrosis at 30%. Findings indicated that the infection in the old aged patient, infection for long period, chronic hepatic inflammation, steatosis, insulin resistance and alcohol drinking affected the rapid fibrosis progression. Having treatment from F0-F1 stage was count for the long-term benefit as it reduced the development of advanced fibrosis for 15% and the survival rate at 15 years better than the non - treatment group, since it minimized the chance of cirrhosis and the extrahepatic mortality.After viral eradication, it would minimize health service and following up expenses on chronic patients.Symptom conditions such as fatique, impaired cognitive function, obsessive-compulsive, depression,and anxiety were improved that affected the better quality of life. The expenses and longer quality-adjustlife year of the treatment from minimal or no fibrotic stage should be taken into account comparingwith the treatment from significant fibrotic stage according to the health economic evaluation.Early treatment in patients with minimal or no fibrotic stage who had factors affecting the rapidfibrosis progression would result in cost-effectiveness.   Keywords: chronic hepatitis C, fibrosis progression, cost-effectiveness, quality-adjust life years, increment cost effectiveness ratio

Impact of nitazoxanide on sustained virologic response in Egyptian patients with chronic hepatitis C genotype 4

2016 ◽  
Vol 28 (1) ◽  
pp. 42-47 ◽  
Author(s):  
Mohamed A.S. Kohla ◽  
Hala El-Said ◽  
Ashraf El-Fert ◽  
Nermine Ehsan ◽  
Sameera Ezzat ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Sustained Virologic Response ◽  
Virologic Response ◽  
Genotype 4 ◽  
Egyptian Patients

The role of ITPA and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anaemia in chronic hepatitis C Egyptian patients

2017 ◽  
Vol 44 (9) ◽  
pp. 965-968 ◽  
Author(s):  
Ehab S El Desoky ◽  
Alaa T Abdelhafez ◽  
Jessica Cusato ◽  
Sherif I Kamel ◽  
Abeer MR Hussein ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Egyptian Patients

scholarly journals The Association of XRCC1 Gene Polymorphisms and Chronic Hepatitis C Induced Insulin Resistance in Egyptian Patients

Cells ◽  
2018 ◽  
Vol 7 (11) ◽  
pp. 185
Author(s):  
Salwa Abo El-khair ◽  
Mona Arafa ◽  
Tarek Besheer ◽  
Ahmed El-Eraky ◽  
Ayman Elsamanoudy
Keyword(s):  
Insulin Resistance ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Gene Polymorphisms ◽  
Nucleotide Polymorphisms ◽  
Xrcc1 Gene ◽  
Egyptian Patients ◽  
Pcr Rflp ◽  
Chronic Hcv

Chronic hepatitis C is implicated in insulin resistance (IR) susceptibility. An X-ray repair cross-complementing group 1 gene (XRCC1) is proposed to be a candidate gene for a study of IR susceptibility. So, this study aims to investigate the possible association of the XRCC1 gene polymorphisms with the risk of IR related to chronic hepatitis C virus (HCV) infection in Egyptian patients. In a case-control study, a total of 210 subjects, including 140 chronic HCV patients (87 patients with IR and 53 without IR) and 70 healthy controls, were included. Two genetic polymorphisms (c.1254C > T and c.1517G > C) of the XRCC1 gene were genotyped via the PCR-restriction fragment length polymorphism (PCR-RFLP) technique. The result of the current study revealed that these two single nucleotide polymorphisms (SNPs) have statistically significant influences on susceptibility to IR in chronic HCV infected Egyptian patients. It could be concluded that c.1254C > T, the TT genotype, CT/CC carriers as well as c.1517G > C, the CC genotype and GC/GG carriers might be associated with increased IR susceptibility. Moreover, T-allele of c.1254C > T and the C-allele of c.1517G > C genetic variants might influence the susceptibility.

Steatosis evolution is a main determinant of fibrosis progression in untreated patients with chronic hepatitis C

2002 ◽  
Vol 36 ◽  
pp. 102-103
Author(s):  
Laurent Castera ◽  
Christophe Hezode ◽  
Francoise Roudot-Thoraval ◽  
Anne Bastie ◽  
Elie-Serge Zafrani ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Main Determinant ◽  
Fibrosis Progression
Sign in / Sign up

Export Citation Format

Share Document